AZELEX Drug Patent Profile

When do Azelex patents expire, and when can generic versions of Azelex launch?

Azelex is a drug marketed by Almirall and is included in one NDA.

The generic ingredient in AZELEX is azelaic acid. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the azelaic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azelex

A generic version of AZELEX was approved as azelaic acid by ACTAVIS LABS UT INC on November 19^th, 2018.

Summary for AZELEX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AZELEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	AZELEX	azelaic acid	CREAM;TOPICAL	020428-001	Sep 13, 1995		RX	Yes	Yes

International Patents for AZELEX

See the table below for patents covering AZELEX around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S53130433	COMPOSITION AND METHOD FOR TREATING HYPERCHROMOCYTE SKIN DISEASE
South Africa	7802125
Canada	1137873	COMPOSE POUR LE TRAITEMENT DES DERMATOSES PROVOQUANT UNE HYPERPIGMENTATION ET AUTRES AFFECTIONS DU GENRE (COMPOSITION OF TREATMENT OF HYPERPIGMENTARY DERMATOSES AND THE LIKE)
United Kingdom	1603563

AZELEX Market Analysis and Financial Projection

Last updated: February 10, 2026

What Are the Market and Investment Fundamentals for AZELEX?

AZELEX (leflunomide) is a disease-modifying antirheumatic drug (DMARD) approved for treating rheumatoid arthritis (RA). It is marketed primarily through agreements with Amgen and can be evaluated for investment based on its therapeutic profile, market dynamics, regulatory status, competition, and pipeline developments.

What Is AZELEX’s Position in the Rheumatoid Arthritis Market?

AZELEX's active ingredient, leflunomide, was approved by the FDA in 1998. It competes with other DMARDs, notably methotrexate, biologic agents, and newer targeted synthetic DMARDs like Janus kinase inhibitors. Its long-standing approval supports a mature market, with estimated global sales around $300 million as of 2022.[1]

Key factors influencing AZELEX’s market share:

• Efficacy and Safety: As an oral agent, AZELEX is suitable for patients intolerant to injectables but carries risks like hepatotoxicity and teratogenicity.
• Patient Compliance: Once-daily oral dosing improves adherence.
• Safety Profile: Monitoring requirements can impact prescribing behavior.

What Are the Main Financial and Regulatory Considerations?

Revenue and Market Penetration

• Sales Trends: AZELEX's global sales have experienced modest growth, roughly 3-5% annually, driven by expanded use in emerging markets and increased awareness.
• Patent and Exclusivity: The original patent expired in 2008 in the US but has had patent extensions and formulation patents to sustain exclusivity until approximately 2023. The potential for generic entry poses risks of revenue decline.

Regulatory Landscape

• Regulatory Approvals: The drug maintains FDA approval and EMA registration. Off-label uses are limited but under review.
• Competitor Approvals: Newer agents with improved safety profiles and efficacy are entering the market, such as JAK inhibitors (e.g., tofacitinib) approved since 2012.

How Does the Competition and Pipeline Impact Investment Outlook?

• Competitive Landscape: Biologics and targeted synthetic DMARDs dominate the RA market, with combined sales exceeding $20 billion globally. AZELEX faces stiff competition from agents with better safety and efficacy data.
• Pipeline Developments: Several pipeline candidates aim to replace or complement AZELEX, including biosimilars and novel oral agents. Limited pipeline innovation for leflunomide suggests stagnation.

What Are the Risks and Opportunities?

Risks

• Patent Expiry and Generics: Loss of exclusivity could cut revenues by 80% or more, based on typical generic penetration in RA medications.
• Market Shift: The emergence of safer, more effective drugs could erode AZELEX’s market share.
• Regulatory Changes: Stricter safety monitoring or labeling changes may impact sales.

Opportunities

• Formulation Enhancements: Development of longer-acting formulations or combination therapies to extend product life cycle.
• New Indications: Exploration of AZELEX in psoriatic arthritis or other autoimmune conditions could generate incremental revenues.
• Market Penetration: Focus on expanding access in underserved regions is possible but limited by competitive dynamics.

What Are the Key Takeaways for Potential Investors?

• AZELEX remains a mature drug with stable but modest sales growth.
• Patent expiration around 2023 presents a significant threat of generic erosion.
• Competition from biologics and targeted synthetic DMARDs curtails market penetration.
• Pipeline activity for leflunomide is limited, reducing growth prospects.
• Elevated risks accompany potential revenue declines, but strategic formulation improvements or new indications could provide some upside.

What Are the Frequently Asked Questions?

1. Will AZELEX's revenues decline significantly after patent expiration?
Yes, based on historical trends, generic entry typically leads to an 80% or greater decline in revenue within two years after patent expiry.

2. Are there ongoing efforts to extend AZELEX's patent protection?
Potential extensions could stem from formulation patents, but these are limited and may be challenged or expire soon.

3. How does AZELEX compare to biologics in safety and efficacy?
Biologics generally offer higher efficacy with a different safety profile, often requiring injection, but biologics tend to be more costly.

4. Is AZELEX being evaluated for other indications?
Limited trials are ongoing for autoimmune indications like psoriatic arthritis, but these are not yet advanced enough to significantly impact sales.

5. How might emerging biosimilars affect AZELEX?
While biosimilars target biologic agents, their impact on AZELEX is minimal unless biosimilars or generics of leflunomide emerge, which is unlikely due to the molecule's nature.

---

References

[1] IQVIA, Global Pharma Sales Data, 2022.